World Orphan Drug Congress 2012–Industry Survey Report 29 May 2012 / By matt turner / Reports / 0 comments
What are the challenges when translating rare disease research into clinical development? 10 May 2012 / By matt turner / Clinical Trials, Orphan Drugs / 0 comments
How to avoid late stage attrition rates when developing #orphandrugs 10 May 2012 / By matt turner / Orphan Drugs / 0 comments
Common mistakes to avoid during late stage #orphandrug development 10 May 2012 / By matt turner / Orphan Drugs / 0 comments
What are the benefits of adaptive clinical trial design for your #orphandrug? #rarediseases 10 May 2012 / By matt turner / Clinical Trials, Orphan Drugs / 0 comments
Top 12 major challenges for #orphandrug clinical trial design 9 May 2012 / By matt turner / Clinical Trials, Orphan Drugs / 0 comments
How was the first-ever allogeneic cell-based product approved by the FDA? 26 April 2012 / By matt turner / Regulation and Government / 0 comments
Gamida Cell has completed patient recruitment for its StemEx trial #regenerativemedicine 20 March 2012 / By matt turner / Clinical Trials, Regenerative Medicine / 0 comments
Hear how Lysogene discussed and validated their approach into clinical trials#raredisease 7 March 2012 / By matt turner / Clinical Trials, Orphan Drugs / 0 comments
Why patient organisations are an essential partner for a sustainable orphan drug company #rarediseases 7 March 2012 / By matt turner / Orphan Drugs / 0 comments
